#### CMP: ₹ 14133

Target: ₹ 16880 (19%)

# Target Period: 12 months

BUY

February 10, 2020

# Growth, margin expansion of power brands to the fore

The 9MFY20 revenues grew 13.3% YoY to ₹ 3132 crore, mainly due to strong growth in key therapies & power brands. EBITDA margins improved 365 bps YoY to 19.7% mainly due to better operational leverage and impact of Ind-As 116. EBITDA grew 39% YoY to ₹ 618 crore. Net profit grew 46% YoY to ₹ 482 crore. Delta vis-à-vis EBITDA was mainly due to lower tax rate.

# "Power brands" continue to grow ahead of industry growth

Abbott India is the fastest growing listed MNC pharma company. It has outperformed the industry on a consistent basis in women's health, GI, metabolic, pain, CNS and vaccines. The company's top 10 brands including (Duphaston- gynaecological, Thyronorm – thyroid, Udiliv, Vertin and Duphalac– GI) have together registered a revenue CAGR of ~18% during December 2015-19 (MAT basis). This has led their combined contribution in total revenues to grow from 51% in December 2015 to ~60% in December 2019. Thus, it is evident that revenue growth has been driven by top brands (power brands). Apart from this, continuous new launches and line extension (more than 100 products launched in 10 years) in existing and new segments is also driving growth. We expect future launches of new products from its key divisions, along with brand extensions and access to innovative molecules from global parent to drive growth.

## Margin improvement with better return ratios

Abbott India is a debt-free company and has seen its core RoEs improving from 72% in FY14 to 113% in FY19. EBITDA margins have recovered from lows of 11.8% in FY14 (due to inclusion of one its top brand (Thyronorm) under price control) to 19.7% in 9MFY20. Apart from this, recent tax amendments have the effect of reducing the company's tax rate from 36% in FY19 to 25.2% from FY20 onwards. Continued new product launches, volume led growth in Abbott India's top brands and intermittent price hikes in its portfolio provide comfort on overall financials. The company has maintained a dividend payout of  $\sim$ 35% in the past four years with cash/share of ₹ 793 in FY19.


## Valuation & Outlook

The domestic pharma industry is expected to grow in the range of 9-11% per annum. Issues such as NLEM and other regulatory aspects are mostly in the price. On the flip side, the looming threat of Jan Aushadhi and trade generics are some head winds at this juncture. However, we continue to believe in Abbott's strong growth track in power brands and capability of new launches on a fairly consistent basis (100 products in the last 10 years). We expect revenues, EBITDA and PAT to grow at ~13%, 25% and 30% CAGR, respectively, in FY19-22E. We maintain **BUY** and arrive at a target price of ₹ 16880 based on 36x FY22 EPS of ₹ 469.



Particulars	
Particular	Amount
Market Capitalisation	₹ 30032 crore
Debt (FY19)	₹ 0 crore
Cash (FY19)	₹ 1684 crore
EV	₹ 28347 crore
52 week H/L	14763/7138
Equity capital	₹ 21.3 crore
Face value	₹ 10

#### Price Performance Graph



#### **Research Analyst**

Siddhant Khandekar siddhant.khandekar@icicisecurities.com

Mitesh Shah, CFA mitesh.sha@icicisecurities.com

Sudarshan Agarwal sudarshan.agarwal@icicisecurities.com

es, EBITDA and F	PAT to grow a	t ~13%, 25%	6 and 30%		
, in FY19-22E. W	le maintain <b>BU</b>	IY and arrive	at a target		
sed on 36x FY22 I	EPS of ₹ 469.				
/					
	FY19	FY20E	FY21E	FY22E	CAGR FY19-22 (%)
	3678.6	4147.8	4685.9	5304.3	13.0
	604.7	846.4	1017.1	1193.8	25.4
	16.4	20.4	21.7	22.5	
	450.3	667.0	832.4	996.2	30.3
	211.9	313.9	391.7	468.8	
	66.7	45.0	36.1	30.1	

Source: ICICI Direct Research; Company

**Key Financial Summary** 

EBITDA margins (%)

₹ Crore Revenues EBITDA

Net Profit EPS (₹) PE (x) **Company Update** 

Company Update | Abbott India

BRAND	Therapy	DEC 15	DEC 16	<b>DEC 17</b>	DEC 18	DEC 19 CA	GR 5yrs
DUPHASTON	Gynaec	166.7	197.4	244.9	335.3	390.1	23.7
THYRONORM	Hormone	170.5	192.0	234.1	331.1	351.9	19.9
UDILIV	GI	118.7	148.9	185.0	226.6	275.1	23.4
VERTIN	CNS	120.7	130.8	146.0	163.0	175.8	9.9
DUPHALAC	GI	109.2	121.7	131.7	148.7	167.9	11.4
SIMILAC	Vitamins	48.1	82.5	103.3	123.6	121.4	26.1
CREMAFFIN PLUS	GI	43.7	58.2	70.5	85.8	106.9	25.0
CREMAFFIN	GI	73.5	83.0	85.6	90.9	106.5	9.7
ENSURE	Vitamins	47.1	49.0	59.2	81.7	106.0	22.5
DIGENE	GI	74.8	82.3	88.8	78.8	95.6	6.3
Тор 10		973.0	1145.7	1349.1	1665.5	1897.3	18.2
Total Revenues		1915.7	2122.7	2401.8	2806.3	3170.7	13.4
Top 10 % of revenue	es	51%	54%	56%	59%	60%	

Exhibit 2: Therapeutic break-up						
Therapy	DEC 15	<b>DEC 16</b>	<b>DEC 17</b>	DEC 18	DEC 19	CAGR 5yrs
GI	627.3	736.2	830.2	912.5	1057.9	14.0
VITAMINS / MINERALS	409.6	455.2	504.9	569.6	611.4	10.5
GYNAECOLOGICAL	216.3	255.3	309.4	414.1	482.2	22.2
NEURO / CNS	287.9	289.0	312.3	349.0	380.1	7.2
HORMONES	174.7	196.1	238.3	337.5	358.5	19.7
ANTI-INFECTIVES	81.3	72.4	68.7	78.9	102.4	5.9
DERMA	27.2	31.3	37.4	39.9	49.3	16.1
CARDIAC	27.2	26.5	29.9	34.3	39.2	9.6
Pain / Analgesics	36.0	32.3	34.7	30.9	39.2	2.1
VACCINES	3.0	11.6	21.0	21.1	31.9	80.4
RESPIRATORY	10.1	10.1	11.0	12.0	11.3	2.9

Source: AlOCD; Company

## **Financial Summary**

Year-end March	FY19	FY20E	FY21E	FY22E
Total Operating Income	3,678.6	4,147.8	4,685.9	5,304.3
Growth (%)	11.5	12.8	13.0	13.2
Raw Material Expenses	2,088.6	2,323.6	2,625.1	2,971.6
Gross Profit	1,590.0	1,824.1	2,060.8	2,332.7
Gross Profit Margins (%)	43.2	44.0	44.0	44.0
Employee Expenses	435.6	471.9	519.1	571.7
Other Expenditure	549.7	505.8	524.6	567.3
Total Operating Expenditure	3,073.9	3,301.4	3,668.8	4,110.5
EBITDA	604.7	846.4	1,017.1	1,193.8
Growth (%)	15.3	40.0	20.2	17.4
Interest	2.3	7.6	6.8	6.1
Depreciation	16.9	59.9	61.9	68.5
Other Income	113.3	112.4	164.0	212.2
PBT before Exceptional Item	698.9	891.4	1,112.4	1,331.3
Less: Exceptional Items	0.0	0.0	0.0	0.0
PBT after Exceptional Items	698.9	891.4	1,112.4	1,331.3
Total Tax	248.5	224.4	280.0	335.1
PAT before MI	450.3	667.0	832.4	996.2
РАТ	450.3	667.0	832.4	996.2
Growth (%)	12.2	48.1	24.8	19.7
EPS (Adjusted)	211.9	313.9	391.7	468.8

Year-end March	FY19	FY20E	FY21E	FY22E
Profit/(Loss) after taxation	442.2	667.0	832.4	996.2
Add: Depreciation & Amortiza	16.9	59.9	61.9	68.5
Net Increase in Current Asset	-51.6	-132.0	-150.5	-171.9
Net Increase in Current Liabili	186.0	104.0	118.3	134.9
Others	-94.4	7.6	6.8	6.1
CF from Operating activities	499.1	706.4	869.0	1,033.9
Investments	-554.1	0.0	0.0	0.0
(Purchase)/Sale of Fixed Ass	4.5	-101.9	-30.0	-30.0
Others	846.2	50.7	-4.9	-4.4
CF from Investing activities	296.6	-51.2	-34.9	-34.4
(inc)/Dec in Loan	0.0	0.0	0.0	0.0
Dividend & Dividend tax	-140.9	-230.6	-276.2	-318.7
Other	-1.9	-7.6	-6.8	-6.1
CF from Financing activities	-142.8	-238.1	-283.1	-324.9
Net Cash Flow	652.9	417.1	551.0	674.6
Cash and Cash Equivalent	1,031.4	1,684.3	2,101.4	2,652.4
Cash	1,684.3	2,101.4	2,652.4	3,327.1
Free Cash Flow	503.6	604.5	839.0	1,003.9

Source: ICICI Direct Research

Year-end March	FY19	FY20E	FY21E	FY22E
Equity Capital	21.3	21.3	21.3	21.3
Reserve and Surplus	1,987.3	2,423.8	2,980.0	3,657.5
Total Shareholders funds	2,008.6	2,445.1	3,001.2	3,678.7
Total Debt	0.0	0.0	0.0	0.0
Deferred Tax Liability	0.0	0.0	0.0	0.0
Long-Term Provisions	75.4	83.0	91.3	100.4
Lease Liability	0.0	50.6	45.6	41.0
Source of Funds	2,084.0	2,578.6	3,138.1	3,820.1
Gross Block - Fixed Assets	164.5	266.4	296.4	326.4
Accumulated Depreciation Net Block	59.6 105.0	119.4 147.0	181.3 115.1	249.8 76.6
	0.7		0.7	
Capital WIP		0.7		0.7
Fixed Assets	105.7	147.7	115.8	77.3
Investments	0.0	0.0	0.0	0.0
Other Non Current Assets	74.2	81.7	89.8	98.8
Inventory	606.8	684.2	772.9	875.0
Debtors	276.1	311.3	351.7	398.1
Loans and Advances	66.2	72.8	80.1	88.1
Other Current Assets	127.6	140.3	154.4	169.8
Cash	1,684.3	2,101.4	2,652.4	3,327.1
Total Current Assets	2,761.0	3,310.1	4,011.6	4,858.1
Creditors	663.5	748.1	845.2	956.8
Provisions	104.0	114.4	125.8	138.4
Other Current Liabilities	89.4	98.4	108.2	119.0
Total Current Liabilities	856.9	960.9	1,079.2	1,214.1
Net Current Assets	1,904.1	2,349.2	2,932.4	3,644.0
Application of Funds	2,084.0	2,578.6	3,138.0	3,820.1

Exhibit 6: Key Ratios (₹ crore) FY20E FY21E FY22E Year-end March FY19 Per share data (₹) Reported EPS 211.9 313.9 391.7 468.8 Cash EPS 133.6 205.4 261.7 318.8 BV per share 945.2 1,150.7 1,412.4 1,731.2 Cash per Share 792.6 988.9 1,248.2 1,565.7 Dividend per share 78.4 108.5 130.0 150.0 **Operating Ratios (%)** 43.2 **Gross Profit Margins** 44.0 44.0 44.0 22.5 **EBITDA** margins 16.4 20.4 21.7 PAT Margins 18.8 12.2 16.1 17.8 **Cash Conversion Cycle** 21.8 21.8 21.8 21.8 Asset Turnover 16.3 22.4 15.6 15.8 **EBITDA conversion Rate** 82.5 83.5 85.4 86.6 **Return Ratios (%)** RoE 22.4 27.3 27.7 27.1 RoCE 33.9 35.1 35.8 35.2 RolC 170.2 203.6 152.3 236.9 Valuation Ratios (x) P/E 45.0 36.1 30.1 66.7 EV / EBITDA 46.9 33.0 26.9 22.4 EV / Net Sales 5.0 7.7 6.7 5.8 Market Cap / Sales 8.2 7.2 6.4 5.7 Price to Book Value 15.0 12.3 10.0 8.2 **Solvency Ratios** Debt / EBITDA 0.0 0.0 0.0 0.0 Debt / Equity 0.0 0.0 0.0 0.0 **Current Ratio** 1.3 1.3 1.3 1.3

Source: ICICI Direct Research

pankaj.pandey@icicisecurities.com

# **RATING RATIONALE**

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%; Hold: -5% to 15%; Reduce: -5% to -15%; Sell: <-15%



Pankaj Pandey

Head – Research

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

### ANALYST CERTIFICATION

We /l, Siddhant Khandekar, Inter CA, Mitesh Shah, CFA, Sudarshan Agarwal, PGDM(Finance), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report.

### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risk associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.